No results for ‘’
Torrent Pharmaceuticals Ltd
₹4429.80
(0.35%)
Thu, 25 Jun 2026, 00:44 am
Health Technology
Pharmaceuticals: Major
24.5KTorrent Pharmaceuticals Debt to Equity Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 32.77 | 17.85 | 8.88 | 6.15 | 19.95 | 18.11 | 18.73 | 13.59 | 13.35 | 26.16 | 13.08 | 28.08 | 31.14 | 75.72 | 32.56 | 34.35 | 60.89 | 41.78 | 53.15 | 57.28 |
| Price to book ratio | 5.29 | 4.07 | 2.35 | 1.74 | 5.55 | 4.82 | 4.48 | 4.16 | 4.67 | 7.89 | 6.49 | 6.03 | 4.57 | 6.99 | 6.92 | 7.37 | 7.95 | 8.39 | 12.84 | 14.42 |
| Price to sales ratio | 1.97 | 1.32 | 0.91 | 0.72 | 2.52 | 2.31 | 2.05 | 1.93 | 2.20 | 4.30 | 3.46 | 4.57 | 3.57 | 4.35 | 4.25 | 5.41 | 5.58 | 5.46 | 8.30 | 9.64 |
| Price to cash flow ratio | 83.94 | 29.84 | 5.38 | 4.54 | 16.94 | 12.55 | 10.50 | 37.63 | 15.54 | 31.01 | 8.94 | 31.87 | 33.81 | 25.36 | 36.09 | 25.99 | 30.48 | 25.04 | 30.27 | 46.72 |
| Enterprise value | 2022Cr | 1947Cr | 1443Cr | 1392Cr | 4762Cr | 4880Cr | 5103Cr | 5830Cr | 8968Cr | 21274Cr | 23546Cr | 26759Cr | 26097Cr | 37880Cr | 38536Cr | 47134Cr | 50802Cr | 56672Cr | 91077Cr | 112000Cr |
| Enterprise value to EBITDA ratio | 26.58 | 15.60 | 8.66 | 5.40 | 13.78 | 15.96 | 11.29 | 10.57 | 9.51 | 21.46 | 8.52 | 20.02 | 19.65 | 19.36 | 17.86 | 18.94 | 21 | 20.13 | 27.36 | 30.73 |
| Debt to equity ratio | 0.76 | 0.73 | 0.72 | 0.75 | 0.65 | 0.58 | 0.49 | 0.49 | 0.60 | 1.10 | 0.67 | 0.58 | 1.40 | 1.28 | 1.21 | 0.84 | 0.68 | 0.87 | 0.59 | 0.42 |
| Return on equity % | 16.95 | 24.67 | 29.28 | 31.78 | 31.20 | 29.25 | 25.78 | 33.25 | 40.09 | 34.24 | 57.92 | 23.80 | 15.12 | 9.34 | 21.47 | 23.49 | 13.18 | 20.50 | 25.38 | 26.46 |
Torrent Pharmaceuticals Ltd Debt to Equity Ratio
The Torrent Pharmaceuticals Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Torrent Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Torrent Pharmaceuticals Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM, BSE: 500420) is currently trading at ₹4429.80, with a market capitalization of ₹150360.2Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Torrent Pharmaceuticals Ltd Debt to Equity Ratio is essential for fundamental analysis.
Torrent Pharmaceuticals Ltd Debt to Equity Ratio Current Value
The current Torrent Pharmaceuticals Ltd Debt to Equity Ratio stands at 0.42.
The Torrent Pharmaceuticals Ltd Debt to Equity Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Torrent Pharmaceuticals Ltd Debt to Equity Ratio Historical Trend
The Torrent Pharmaceuticals Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.42
- 2023: 0.59
- 2022: 0.87
- 2021: 0.68
- 2020: 0.84
The decline in Torrent Pharmaceuticals Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What Torrent Pharmaceuticals Ltd Debt to Equity Ratio Indicates for Investors
The Torrent Pharmaceuticals Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Torrent Pharmaceuticals Ltd Debt to Equity Ratio Analysis Summary
The Torrent Pharmaceuticals Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Torrent Pharmaceuticals Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Torrent Pharmaceuticals Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.